IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Glioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Glioma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3

IDH2 mutation + Chr del(1p) + Chr del(19q)

Associations